Single-dose CanSinoBIO’s COVID-19 vaccine triggers strong immunity response in children aged between 6-17
One shot of Chinese producer CanSinoBIO’s recombinant COVID-19 vaccine shows good safety and strong immunity response in children aged between 6-17: latest clinical trial data
Photo: CFP
